



EXTENDED APPROVAL FOR USE IN PREGNANT MARES HELPS PROVIDE FLEXIBLE, CONFIDENT EQUINE LEPTOSPIROSIS PROTECTION

LEPTO EQ INNOVATOR®, the only equine vaccine to help prevent leptospirosis caused by *L. pomona*, now offers an additional USDA-licensed label claim — demonstrated safe for use in pregnant horses.^{1,2}

SAFE FOR ALL PHASES OF PREGNANCY

Field safety studies examined LEPTO EQ INNOVATOR when used in the first, second and third trimesters of pregnancy and showed no systemic or local reactions were attributed to the administration of the vaccine.^{1,2} The studies included a total of 457 pregnant mares with each mare being vaccinated twice, three to four weeks apart.

Trimester of Pregnancy	Number of Mares	Number of Vaccinations	Systemic Reactions	Local Reactions
1st	114	228	0	0
2nd	202	397*	0	0
3rd	141	282	0	0
TOTAL	457	907	0	0

*Seven mares received only one vaccination as the mares moved locations, causing them to be removed from the study.

LEPTOSPIRES CAN CAUSE LATE-TERM ABORTIONS

Leptospire can cause late-term abortion in mares. A study showed that 13% of bacterial abortions are caused by *L. pomona*, the most common leptospiral serovar associated with clinical disease in horses.³ Aborting mares have been reported to shed leptospire in their urine for periods up to three months and can transmit *Leptospira* to exposed animals.³ Additionally, the aborted fetus is a source of exposure to other horses on the property.

LEPTO EQ INNOVATOR helps prevent leptospirosis caused by *Leptospira interrogans* serovar Pomona (*L. pomona*) which could, but has not been demonstrated to, help reduce the potential risk of equine recurrent uveitis (ERU) infections, abortions or acute renal failure caused by *L. pomona*.** In intensive safety and efficacy trials, LEPTO EQ INNOVATOR was shown to provide a safe immune response.

- Vaccinated horses showed 0% urinary shedding when challenged with *L. pomona*.⁴
- Field studies showed 99.9% of vaccinated horses were reaction-free with no adverse events.^{1,2,5}

TO LEARN MORE ABOUT **LEPTO EQ INNOVATOR**, VISIT LEPTOEQINNOVATOR.COM OR CONTACT YOUR ZOETIS REPRESENTATIVE.

ONGOING INNOVATION FOR EQUINE DISEASE PREVENTION

Zoetis continues to invest in research and development to bring advanced vaccine solutions to the equine industry. LEPTO EQ INNOVATOR® enriches the broad portfolio of equine vaccines which also includes FLUVAC INNOVATOR®, WEST NILE-INNOVATOR®, PINNACLE® I.N. and PNEUMABORT-K® + 1b.

Based on continued vaccine innovation, the American Association of Equine Practitioners (AAEP) vaccination recommendations were updated to include leptospirosis.⁶ See full list of AAEP broodmare vaccination recommendations below:

AAEP BROODMARE VACCINATION RECOMMENDATIONS⁶

CORE BROODMARE VACCINATIONS

Disease	Previously Vaccinated	Unvaccinated or Unknown History	Zoetis Vaccine Solutions
Tetanus	Annual revaccination, 4-6 weeks prepartum	2 doses – 2nd dose 4-6 weeks after 1st dose	TETANUS TOXOID FLUVAC INNOVATOR® 4, 5 or 6 WEST NILE-INNOVATOR® + EWT WEST NILE-INNOVATOR + VEW
Eastern equine encephalomyelitis and Western equine encephalomyelitis	Annual revaccination, 4-6 weeks prepartum	2 doses – 2nd dose 4-6 weeks after 1st dose	FLUVAC INNOVATOR 4, 5 or 6 WEST NILE-INNOVATOR + EWT
West Nile	Annual revaccination, 4-6 weeks prepartum	2 doses – 2nd dose 4-6 weeks after 1st dose. It is preferable to vaccinate naïve mares when open.	WEST NILE-INNOVATOR + EW WEST NILE-INNOVATOR + EWT WEST NILE-INNOVATOR + VEW
Rabies	Annual revaccination, prior to breeding or 4-6 weeks prepartum	Single dose	

RISK-BASED BROODMARE VACCINATIONS

Disease	Previously Vaccinated	Unvaccinated or Unknown History	Zoetis Vaccine Solutions
Leptospirosis	Annual revaccination	2 doses – 2nd dose 3-4 weeks after 1st dose	LEPTO EQ INNOVATOR®
Equine Viral Arteritis	Annual revaccination, after foaling	Discuss your mare's risk with your veterinarian prior to vaccinating.	ARVAC®
Equine Influenza	Annual or semiannual revaccination, 4-6 weeks prepartum	3-dose series – 2nd dose 4-6 weeks after 1st dose, 3rd dose 3-6 months after 2nd dose	FLUVAC INNOVATOR® FLUVAC INNOVATOR EHV-4/1 FLUVAC INNOVATOR 4, 5 or 6
Equine Herpesvirus — respiratory	Annual revaccination, 4-6 weeks prepartum	3-dose series – 2nd dose 4-6 weeks after 1st dose, 3rd dose 4-6 weeks after 2nd dose	FLUVAC INNOVATOR EHV-4/1 FLUVAC INNOVATOR 5 or 6
Equine Herpesvirus — abortion	3-dose series with product labeled for protection against EHV abortion – give at 5th, 7th and 9th month of pregnancy		PNEUMABORT-K® + 1b

Always follow label directions.

**Currently, there are no vaccines available with USDA-licensed label claims against equine abortions, uveitis or acute renal failure due to *L. pomona*.

References:

¹ Data on file, Study Report No. B951R-US-15-092, Zoetis LLC.

² Data on file, Study Report No. B951R-US-13-046, Zoetis LLC.

³ Divers TJ, Chang Y-F. Leptospirosis. In: Robinson NE, Sprayberry KA, eds. *Current Therapy in Equine Medicine*. Vol 6. 6th ed. St. Louis, Mo: Saunders Elsevier, 2009:145-147.

⁴ Data on file, Study Report No. B850R-US-12-011, Zoetis LLC.

⁵ Data on file, Study Report No. B951R-US-13-043, Zoetis LLC.

⁶ American Association of Equine Practitioners. Vaccination Guidelines. <http://www.aaep.org/info/vaccination-guidelines>. Accessed August 31, 2016.